Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Greenwich LifeSciences, Inc.    GLSI

GREENWICH LIFESCIENCES, INC.

(GLSI)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

GREENWICH LIFESCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

10/09/2020 | 08:05am EST

Item 7.01 Regulation FD Disclosure.

Greenwich LifeSciences, Inc. (the "Company") intends to conduct meetings with third parties in which its corporate slide presentation will be presented. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 8.01 Other Events.


On October 6, 2020, the Company announced the completion of the manufacturing of the GP2 active ingredient for its planned Phase III clinical trial. On October 7, 2020, the Company announced that it was selected to present at the 2020 BIO Investor Forum conference to be held virtually from October 13-15, 2020 and will be participating at the BIO-Europe partnering conference to be held virtually from October 26-29, 2020. On October 8, 2020, the Company announced that two abstracts have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), including two corresponding posters. Copies of the press releases are attached hereto as Exhibits 99.2, 99.3 and 99.4, respectively, and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.




Exhibit No.                         Description

99.1            Greenwich LifeSciences, Inc. Corporate Presentation

99.2            Press release dated October 6, 2020

99.3            Press release dated October 7, 2020

99.4            Press release dated October 8, 2020




-2-

© Edgar Online, source Glimpses

All news about GREENWICH LIFESCIENCES, INC.
01/08GREENWICH LIFESCIENCES : to Participate in Multiple Virtual Investor Conferences..
BU
01/05GREENWICH LIFESCIENCES : rsquo; LD Micro Presentation Replay Now Available
BU
2020GREENWICH LIFESCIENCES : to Ring Nasdaq Opening Bell on December 28
BU
2020GREENWICH LIFESCIENCES, INC. : Entry into a Material Definitive Agreement, Other..
AQ
2020GREENWICH LIFESCIENCES, INC. : Announces Closing of Public Offering of Common St..
BU
2020SECTOR UPDATE : Health Care Stocks Pulled Under in Friday Trading
MT
2020SECTOR UPDATE : Biotech Shares Helping Limit Declines by Health Care Stocks
MT
2020Wall Street Sees Muted Open, Consolidating After Stimulus Rally
MT
2020GREENWICH LIFESCIENCES : Prices Upsized Common Shares Offering at $40 Apiece; Sh..
MT
2020GREENWICH LIFESCIENCES, INC. : Prices $26.4 Million Upsized Public Offering of C..
BU
More news
Financials (USD)
Sales 2019 - - -
Net income 2019 -3,43 M - -
Net Debt 2019 0,63 M - -
P/E ratio 2019 -
Yield 2019 -
Capitalization 476 M 476 M -
EV / Sales 2018 -
EV / Sales 2019 -
Nbr of Employees -
Free-Float 20,0%
Chart GREENWICH LIFESCIENCES, INC.
Duration : Period :
Greenwich LifeSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GREENWICH LIFESCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
NameTitle
Snehal Patel Chief Executive & Financial Officer, Director
David B. McWilliams Chairman
F. Joseph Daugherty Director & Chief Medical Officer
Jaye L. Thompson Vice President Clinical & Regulatory Affairs
Eric Rothe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GREENWICH LIFESCIENCES, INC.2.69%476
CSL LIMITED-5.62%93 853
SAMSUNG BIOLOGICS CO.,LTD.-2.66%48 243
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-2.71%35 533
ALEXION PHARMACEUTICALS, INC.0.26%34 293